Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Allograft Tolerance Through Mixed Chimerism
NCT00801632Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2008
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siplizumab in kidney failure, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks at 48 months. Started Dec 2008; status: completed.
02
Drugs
siplizumab
03
Conditions
kidney failure
Beyond the preview
Go deeper on NCT00801632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00801632.